Spectrum Pharmaceuticals (SPPI) $15.95M Investor Settlement

Spectrum Pharmaceuticals ($ASRT) has agreed to settle $15.95 million with investors to resolve claims that it misled them about the effectiveness and FDA approval prospects of its two lead drug candidates.

Outline

Between 2018 and 2021, Spectrum promoted Poziotinib and Rolontis as promising therapies nearing FDA approval. Internally, however, executives were aware of poor clinical results, side effects, and manufacturing problems. As these issues surfaced, $SPPI fell by over 88%, and investors filed a lawsuit.

Timeline

• December 19, 2018 – FDA denied Breakthrough Therapy Designation for Poziotinib.
• December 26, 2019 – Spectrum announced that Poziotinib’s Cohort 1 trial failed to meet efficacy goals.
• December 22, 2020 – Cohort 3 data also missed targets; $SPPI began a sharp decline.
• August 5, 2021 – Spectrum continued with trial failures and falling share price.
• August 30, 2021 – Investors filed a lawsuit, alleging that Spectrum misled them about clinical results and regulatory risk.
• July 31, 2023 – Spectrum was delisted following its acquisition by Assertio.
• May 9, 2025 – Spectrum agreed to a $15.95 million settlement.

Background

Spectrum Pharmaceuticals was a small biotech firm focused on late-stage drug development. Its pipeline centered around two products: Poziotinib, a treatment for certain lung cancers, and Rolontis, a drug for chemotherapy-related neutropenia.

While promoting both as near approval, Spectrum executives had access to data showing Poziotinib had failed to meet key safety and efficacy benchmarks. Trial participants experienced severe side effects that led to dose reductions and patient withdrawals. Despite this, the company told investors it remained confident in approval.

Rolontis also ran into regulatory issues. The FDA flagged serious manufacturing violations at a partner facility in South Korea, including sanitation issues and procedural lapses that delayed the approval process.

Even as these problems mounted, Spectrum raised more than $100 million through stock offerings, and insiders sold large amounts of personal shares.

After multiple failed trials and FDA rejections, $SPPI dropped nearly 88%.

After that, in August 2021, investors sued Spectrum for misrepresenting the development and approval prospects of its drug candidates.

The company was later acquired and delisted in 2023.

What Can Investors Expect Now?

Spectrum Pharmaceuticals ($ASRT) has agreed to settle $15.95 million with investors to resolve claims that it misled them about the effectiveness and FDA approval prospects of its two lead drug candidates.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section below.